Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 23 May 2016
At a glance
- Drugs BMS 833923 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 21 Dec 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Nov 2011 Planned initiation date changed from 1 Oct 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
- 12 Aug 2011 New trial record